Hubungan Kadar Matrix Metalloproteinase-9 pada Cairan Serebrospinal dan Serum terhadap Derajat Keparahan dan Luaran Pasien Meningitis Tuberkulosis
Isi Artikel Utama
Page: 1979-1985
Abstrak
Tuberkulosis meningitis (TBM) merupakan bentuk TB berat dengan mortalitas dan morbiditas neurologis yang tinggi. Derajat keparahan sangat memengaruhi luaran, namun prediktor biologis yang andal masih terbatas. Matrix metalloproteinase-9 (MMP-9) merupakan enzim proteolitik yang berperan dalam neuroinflamasi dan kerusakan sawar darah otak, serta dilaporkan meningkat pada cairan serebrospinal (CSS) maupun serum pasien TBM. Penelitian ini bertujuan menilai hubungan kadar MMP-9 dengan derajat keparahan dan luaran pasien TBM. Penelitian ini merupakan studi observasional analitik dengan desain cross-sectional pada pasien TBM yang dirawat di RSUP Dr. M. Djamil Padang pada bulan Januari hingga Desember 2024. Kadar MMP-9 CSS dan serum diukur menggunakan metode enzyme linked immunosorbent assay (ELISA). Derajat keparahan dinilai dengan BMRC dan luaran 14 serta 60 hari menggunakan Glasgow Outcome Scale. Terdapat sebanyak 41 pasien TBM pada penelitian. Rerata kadar MMP-9 CSS didapatkan sebesar 2.034,40 ng/L, sementara itu median kadar MMP-9 serum didapatkan sebesar 1.490,14 ng/L. Hasil analisis menunjukkan tidak terdapatnya hubungan bermakna antara kadar MMP-9 CSS dengan derajat keparahan (p = 0,276), luaran 14 hari (p = 0,269), maupun 60 hari (p = 0,375). Kadar MMP-9 serum juga tidak berhubungan dengan derajat keparahan (p = 0,248), luaran 14 hari (p = 0,224), maupun 60 hari (p = 0,138), namun tetap menunjukkan pola peningkatan pada pasien dengan luaran meninggal. Kadar MMP-9 CSS dan serum tidak memiliki hubungan yang bermakna dengan derajat keparahan dan luaran pasien TBM. Temuan ini menunjukkan bahwa MMP-9 tunggal belum cukup dijadikan prediktor klinis, sehingga pendekatan multibiomarker dan pemantauan longitudinal perlu dipertimbangkan.
Unduhan
Rincian Artikel

Artikel ini berlisensiCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Referensi
Gopalaswamy R, Dusthackeer VNA, Kannayan S, Subbian S. Extrapulmonary tuberculosis—an update on the diagnosis, treatment and drug resistance. J Respir. 2021;1(2):141-164. DOI: https://doi.org/10.3390/jor1020015
Arshad A, Dayal S, Gadhe R, et al. Analysis of tuberculosis meningitis pathogenesis, diagnosis, and treatment. J Clin Med. 2020;9(9). DOI: https://doi.org/10.3390/jcm9092962
Navarro-Flores A, Fernandez-Chinguel JE, Pacheco-Barrios N, Soriano-Moreno DR, Pacheco-Barrios K. Global morbidity and mortality of central nervous system tuberculosis. J Neurol. 2022;269(7). DOI: https://doi.org/10.1007/s00415-022-11052-8
Aggarwal A, Singla N, Konar M, et al. Role of microRNAs as post transcription regulators of matrix metalloproteinases and their association in tuberculous meningitis. Tuberculosis (Edinb). 2024;146:102501. DOI: https://doi.org/10.1016/j.tube.2024.102501
Mehta R, Chinthapalli K. Glasgow coma scale explained. BMJ. 2019;365:l1296. DOI: https://doi.org/10.1136/bmj.l1296
Wang MG, Luo L, Zhang Y, Liu X, Liu L, He JQ. Treatment outcomes of tuberculous meningitis in adults. BMC Pulm Med. 2019;19(1):200. DOI: https://doi.org/10.1186/s12890-019-0966-8
Thwaites G. Tuberculous meningitis. Medicine (Abingdon). 2017;45(11):670-673. DOI: https://doi.org/10.1016/j.mpmed.2017.08.010
Daniel BD, Grace GA, Natrajan M. Tuberculous meningitis in children: clinical management & outcome. Indian J Med Res. 2019;150(2):117-130. DOI: https://doi.org/10.4103/ijmr.IJMR_786_17
Widayanti A, Ganiem AR, Parwati I. Association between polymorphonuclear leukocyte percentage in CSF and outcome of TBM. Maj Kedokt Bandung. 2020;52(4):220-226. DOI: https://doi.org/10.15395/mkb.v52n4.1563
Setiawan H, Nugraha J. Analisis kadar IFN-γ dan IL-10 pada tuberkulosis. Jurnal Biosains Pascasarjana. 2016;18(1):1-14. DOI: https://doi.org/10.20473/jbp.v18i1.2016.50-63
Majeed S, Singh P, Sharma N, Sharma S. Role of matrix metalloproteinase-9 in progression of tuberculous meningitis. BMC Infect Dis. 2016;16(1). DOI: https://doi.org/10.1186/s12879-016-1953-9
Aggarwal A, Singla N, Konar M, et al. hsa-miR-885-5p as post transcription regulator of matrix metalloproteinase 9 in tuberculous meningitis. Indian J Clin Biochem. 2024:1-6. DOI: https://doi.org/10.1007/s12291-024-01275-z
Lee HS, Kim WJ. The role of matrix metalloproteinase in inflammation with a focus on infectious diseases. Int J Mol Sci. 2022;23(18). DOI: https://doi.org/10.3390/ijms231810546
Fortova A, Hönig V, Salat J, et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker in paediatric and adult tick-borne encephalitis patients. Virus Res. 2023;324:199020. DOI: https://doi.org/10.1016/j.virusres.2022.199020
Poh XY, Loh FK, Friedland JS, Ong CWM. Neutrophil-mediated immunopathology and matrix metalloproteinases in CNS tuberculosis. Front Immunol. 2022;12:788976. DOI: https://doi.org/10.3389/fimmu.2021.788976
Davis AG, Rohlwink UK, Proust A, Figaji AA, Wilkinson RJ. The pathogenesis of tuberculous meningitis. J Leukoc Biol. 2019;105(2):267-280. DOI: https://doi.org/10.1002/JLB.MR0318-102R
Yuan T, Deng M, Wang Y, et al. Combined cerebrospinal fluid sCD163, MMP-9, with serum NCAM1 protein levels for predicting prognosis. Sci Rep. 2025;15(1):6696. DOI: https://doi.org/10.1038/s41598-025-90391-8
Mailankody S, Dangeti GV, Soundravally R, et al. Cerebrospinal fluid matrix metalloproteinase 9 levels and outcome in TBM. PLoS One. 2017;12(7). DOI: https://doi.org/10.1371/journal.pone.0181262
Rohlwink UK, Walker NF, Ordonez AA, et al. Matrix metalloproteinases in pulmonary and central nervous system tuberculosis. Int J Mol Sci. 2019;20(6):1350. DOI: https://doi.org/10.3390/ijms20061350
Ong CW, Pabisiak PJ, Brilha S, et al. Complex regulation of neutrophil-derived MMP-9 in CNS tuberculosis. J Neuroinflammation. 2017;14(1):31. DOI: https://doi.org/10.1186/s12974-017-0801-1
Turner RJ, Sharp FR. Implications of MMP9 for blood-brain barrier disruption. Front Cell Neurosci. 2016;10:56. DOI: https://doi.org/10.3389/fncel.2016.00056
Kumar NP, Moideen K, Nancy A, et al. Association of plasma matrix metalloproteinase and tissue inhibitors of matrix metalloproteinase levels with adverse treatment outcomes. JAMA Netw Open. 2020;3(12). DOI: https://doi.org/10.1001/jamanetworkopen.2020.27754
Dian S, Koeken VACM, Ardiansyah E, et al. Inflammatory markers in the cerebrospinal fluid linked to mortality in tuberculous meningitis. Brain Commun. 2025;7(4):fcaf273. DOI: https://doi.org/10.1093/braincomms/fcaf273
Manyelo CM, Solomons RS, Walzl G, Chegou NN. Tuberculous meningitis: pathogenesis and biomarkers. J Clin Microbiol. 2021;59(3). DOI: https://doi.org/10.1128/JCM.01771-20
Zakiyyah NC, Gunadharma S, Ganiem AR. Outcomes of tuberculous meningitis patients with or without hydrocephalus. Althea Med J. 2022;9(4):198-205. DOI: https://doi.org/10.15850/amj.v9n4.2304
Wang L, Gu Z, Chen X, Yu X, Meng X. Risk factors for long-term mortality in tuberculous meningitis. BMC Infect Dis. 2024;24(1):656. DOI: https://doi.org/10.1186/s12879-024-09561-0
Navasardyan I, Yeganyan S, Nguyen H, Vaghashia P, Subbian S, Venketaraman V. Role of oxidative stress in tuberculosis meningitis infection in diabetics. Biomedicines. 2023;11(9):2568. doi:10.3390/biomedicines11092568. DOI: https://doi.org/10.3390/biomedicines11092568